Safety of ibuprofen vs. paracetamol

Gregory M. Peterson, Mark Naunton

Research output: Contribution to journalLetter

Abstract

What are readers and the public to make of the study by de Vries et al. 1 ? At a glance, it appears that the safety profiles of ibuprofen, paracetamol and the combination of the two drugs are similar. Do the results of this study, funded by the principal manufacturer of ibuprofen, hold up to closer scrutiny? This was not a prospective randomized controlled trial. It was a retrospective observational study. Importantly, we cannot assume that individuals were equally likely to have been prescribed the three options studied (ibuprofen alone, paracetamol alone or concomitant ibuprofen and paracetamol). There are some major confounding effects at play here. One might anticipate, for instance, that patients with a history of heart disease, peptic ulcers or renal disease would be less likely to have been prescribed a nonsteroidal anti‐inflammatory drug (NSAID), compared with paracetamol, in the first place. Indeed, it is clear from table 1 of the publication that there were large and statistically significant differences between the patients retrospectively allocated to the three groups across a number of baseline variables, including age and a past history of heart failure, ischaemic heart disease, cerebrovascular disease and upper gastrointestinal disease.
Original languageEnglish
Pages (from-to)964
Number of pages1
JournalBritish Journal of Clinical Pharmacology
Volume71
Issue number6
DOIs
Publication statusPublished - 1 Jun 2011
Externally publishedYes

Fingerprint

Ibuprofen
Acetaminophen
Safety
Cerebrovascular Disorders
Gastrointestinal Diseases
Drug Combinations
Peptic Ulcer
Observational Studies
Myocardial Ischemia
Publications
Heart Diseases
Anti-Inflammatory Agents
Randomized Controlled Trials
Heart Failure
Retrospective Studies
Kidney
Pharmaceutical Preparations

Cite this

Peterson, Gregory M. ; Naunton, Mark. / Safety of ibuprofen vs. paracetamol. In: British Journal of Clinical Pharmacology. 2011 ; Vol. 71, No. 6. pp. 964.
@article{05813d77e4244d6f8dcb74463cc3201b,
title = "Safety of ibuprofen vs. paracetamol",
abstract = "What are readers and the public to make of the study by de Vries et al. 1 ? At a glance, it appears that the safety profiles of ibuprofen, paracetamol and the combination of the two drugs are similar. Do the results of this study, funded by the principal manufacturer of ibuprofen, hold up to closer scrutiny? This was not a prospective randomized controlled trial. It was a retrospective observational study. Importantly, we cannot assume that individuals were equally likely to have been prescribed the three options studied (ibuprofen alone, paracetamol alone or concomitant ibuprofen and paracetamol). There are some major confounding effects at play here. One might anticipate, for instance, that patients with a history of heart disease, peptic ulcers or renal disease would be less likely to have been prescribed a nonsteroidal anti‐inflammatory drug (NSAID), compared with paracetamol, in the first place. Indeed, it is clear from table 1 of the publication that there were large and statistically significant differences between the patients retrospectively allocated to the three groups across a number of baseline variables, including age and a past history of heart failure, ischaemic heart disease, cerebrovascular disease and upper gastrointestinal disease.",
author = "Peterson, {Gregory M.} and Mark Naunton",
year = "2011",
month = "6",
day = "1",
doi = "10.1111/j.1365-2125.2010.03864.x",
language = "English",
volume = "71",
pages = "964",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "6",

}

Safety of ibuprofen vs. paracetamol. / Peterson, Gregory M.; Naunton, Mark.

In: British Journal of Clinical Pharmacology, Vol. 71, No. 6, 01.06.2011, p. 964.

Research output: Contribution to journalLetter

TY - JOUR

T1 - Safety of ibuprofen vs. paracetamol

AU - Peterson, Gregory M.

AU - Naunton, Mark

PY - 2011/6/1

Y1 - 2011/6/1

N2 - What are readers and the public to make of the study by de Vries et al. 1 ? At a glance, it appears that the safety profiles of ibuprofen, paracetamol and the combination of the two drugs are similar. Do the results of this study, funded by the principal manufacturer of ibuprofen, hold up to closer scrutiny? This was not a prospective randomized controlled trial. It was a retrospective observational study. Importantly, we cannot assume that individuals were equally likely to have been prescribed the three options studied (ibuprofen alone, paracetamol alone or concomitant ibuprofen and paracetamol). There are some major confounding effects at play here. One might anticipate, for instance, that patients with a history of heart disease, peptic ulcers or renal disease would be less likely to have been prescribed a nonsteroidal anti‐inflammatory drug (NSAID), compared with paracetamol, in the first place. Indeed, it is clear from table 1 of the publication that there were large and statistically significant differences between the patients retrospectively allocated to the three groups across a number of baseline variables, including age and a past history of heart failure, ischaemic heart disease, cerebrovascular disease and upper gastrointestinal disease.

AB - What are readers and the public to make of the study by de Vries et al. 1 ? At a glance, it appears that the safety profiles of ibuprofen, paracetamol and the combination of the two drugs are similar. Do the results of this study, funded by the principal manufacturer of ibuprofen, hold up to closer scrutiny? This was not a prospective randomized controlled trial. It was a retrospective observational study. Importantly, we cannot assume that individuals were equally likely to have been prescribed the three options studied (ibuprofen alone, paracetamol alone or concomitant ibuprofen and paracetamol). There are some major confounding effects at play here. One might anticipate, for instance, that patients with a history of heart disease, peptic ulcers or renal disease would be less likely to have been prescribed a nonsteroidal anti‐inflammatory drug (NSAID), compared with paracetamol, in the first place. Indeed, it is clear from table 1 of the publication that there were large and statistically significant differences between the patients retrospectively allocated to the three groups across a number of baseline variables, including age and a past history of heart failure, ischaemic heart disease, cerebrovascular disease and upper gastrointestinal disease.

UR - http://www.scopus.com/inward/record.url?scp=79955836883&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2125.2010.03864.x

DO - 10.1111/j.1365-2125.2010.03864.x

M3 - Letter

VL - 71

SP - 964

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 6

ER -